Aurobindo Pharma subsidiary Eugia Pharma Specialities has received the final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Icatibant injection, 30 mg/3 mL (10 mg/mL), single-dose prefilled syringe.
Eugia Pharma's Generic Icatibant Acetate Receives Approval in the U.S.
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of SAJAZIR™ (icatibant) Injection, a new treatment option for patients affected by Hereditary Angioedema (HAE) approved by the US Food and Drug Administration (FDA).
Glenmark Pharma`s Generic Icatibant Acetate Receives Approval In US
Glenmark Pharma's Generic Icatibant Acetate Receives Approval In US
PRINCETON, N.J., Jan. 28, 2021 /PRNewswire/ -- Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of generic Icatibant injection pre-filled syringe to treat acute attacks of rare disease hereditary angioedema (HAE) in adults 18 years and older.1 It is available immediately for US patients.
Nang Kuang`s Generic Icatibant Acetate Receives Tentative Approval In US
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced icatibant injection in the United States with immediate availability. Icatibant injection is an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema (HAE) in adults.
Dr Reddys's Generic Icatibant Acetate Receives Approval In US
Slayback Pharma's Generic ICATIBANT ACETATE Receives Approval In The US